Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3690

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_172605
Pages: 150
Oct 2017 | 2888 Views
face gplus_n
Author's : Onkar Sumant and Tenzin Kunsel
Tables: 33
Charts: 27
twit_n pr_n

Cancer Gene Therapy Market Overview:

Cancer Gene Therapy Market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023. With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.

Due to the high success rate during the preclinical and clinical trial, cancer gene therapy is gaining popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.

The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy, oncolytic virotherapy, and gene transfer. Gene induced immunotherapy is further segmented into delivery of cytokines gene and delivery of tumor antigen gene.

Oncolytic virotherapy is further categorized into adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others. Gene transfer is further classified into naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to overcome the effect of restraints. Moreover, the technological advancements leading to higher adoption rate and untapped markets in developing economies are expected to provide new avenues for the growth of cancer gene therapy market in the near future

Drivers and Restraints

Drivers and Restraints

Cancer gene therapy Market: Key Geographic Segment

North America accounted for the largest market share in the cancer gene therapy market in 2016, and is expected to retain its dominance throughout the forecast period.

Cancer Gene Therapy Market, by Region, 2016 (%)

Cancer Gene Therapy Market, by Region, 2016 (%)

The key players operating in the global cancer gene therapy market include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

Other prominent players in the value chain include Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBiono GeneTech, and Altor Bioscience.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis, based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Cancer Gene Therapy Market Key Segments:

By Therapy

  • Gene Induced Immunotherapy
    • Delivery of Cytokines Gene
    • Delivery of Tumor Antigen Gene
  • Oncolytic Virotherapy
    • Adenovirus
    • Lentivirus
    • Retro Virus
    • Adeno Associated Virus
    • Herpes Simplex Virus
    • Alpha Virus
    • Vaccinia Virus
    • Simian Virus
    • Others
  • Gene Transfer
    • Naked/Plasmid Vectors
    • Electroporation
    • Sonoportion
    • Magnetofection
    • Gene Gun

By End User

  • Hospitals
  • Diagnostics Centers
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. REGULATION AND REIMBURSEMENT SCENARIO
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 CANCER GENE THERAPY MARKET, BY THERAPY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLYTIC VIROTHERAPY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Adenovirus
4.2.5. Lentivirus
4.2.6. Retro virus
4.2.7. Adeno associated virus
4.2.8. Herpes simplex virus
4.2.9. Alpha Virus
4.2.10. Vaccinia Virus
4.2.11. Simian Virus
4.2.12. Others

4.3. GENE TRANSFER

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Naked plasmid vector
4.3.5. Electroporation
4.3.6. Sonoportion
4.3.7. Magnetofection
4.3.8. Gene Gun

4.4. GENE-INDUCED IMMUNOTHERAPY

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Delivery of cytokines gene
4.4.5. Delivery of tumor antigen gene

Chapter: 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Cancer gene therapy Market by Therapy

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Cancer gene therapy Market by Therapy

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. Australia market size and forecast
5.4.3.4. India market size and forecast
5.4.3.5. South Korea market size and forecast
5.4.3.6. Taiwan market size and forecast
5.4.3.7. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Brazil market size and forecast
5.5.3.2. Turkey market size and forecast
5.5.3.3. Saudi Arabia market size and forecast
5.5.3.4. South Africa market size and forecast
5.5.3.5. Rest of LAMEA market size and forecast

5.5.4. LAMEA Cancer gene therapy Market by Therapy

Chapter: 6 COMPANY PROFILES

6.1. ADAPTIMMUNE

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. GLAXOSMITHKLINE

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. BLUEBIRD BIO, INC.

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. MERCK

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. CELGENE

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. SHANGHAI SUNWAY BIOTECH

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. BIOCANCELL

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. SHENZHEN SIBIONO GENETECH

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. SYNERGENE THERAPEUTICS

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. ONCOGENEX PHARMACEUTICALS

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 2. CANCER GENE THERAPY MARKET FOR GENE INDUCED IMMUNOTHERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 3. CANCER GENE THERAPY MARKET FOR ONCOLYTIC VIROTHERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 4. CANCER GENE THERAPY MARKET FOR GENE TRANSFER, BY REGION, 2016-2023 ($MILLION)
TABLE 5. CANCER GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 7. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 8. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 9. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 10. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 12. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 14. ADAPTIMMUNE: COMPANY SNAPSHOT
TABLE 15. ADAPTIMMUNE: OPERATING SEGMENTS
TABLE 16. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 17. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 18. BLUEBIRD: COMPANY SNAPSHOT
TABLE 19. BLUEBIRD: OPERATING SEGMENTS
TABLE 20. MERCK: COMPANY SNAPSHOT
TABLE 21. MERCK: OPERATING SEGMENTS
TABLE 22. CELGENE: COMPANY SNAPSHOT
TABLE 23. CELGENE: OPERATING SEGMENTS
TABLE 24. SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
TABLE 25. SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
TABLE 26. BIOCANCELL: COMPANY SNAPSHOT
TABLE 27. BIOCANCELL: OPERATING SEGMENTS
TABLE 28. SHENZHEN SIBIONO GENETECH: COMPANY SNAPSHOT
TABLE 29. SHENZHEN SIBIONO GENETECH: OPERATING SEGMENTS
TABLE 30. SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 31. SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
TABLE 32. ONCOGENEX PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 33. ONCOGENEX PHARMACEUTICALS: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. SEGMENTATION OF GLOBAL CANCER GENE THERAPY MARKET
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL CANCER GENE THERAPY MARKET 2016
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE (2014-2016)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY (2014-2016)
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL CANCER GENE THERAPY MARKET
FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET: SEGMENTATION BY TYPE
FIGURE 13. U.S. CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 19. REST OF EUROPE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 20. INDIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 21. JAPAN CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 22. CHINA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 23. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 24. BRAZIL CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 25. SOUTH AFRICA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 26. SAUDI ARABIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF LAMEA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

 

The rise in prevalence rate of cancer resulted in high mortality rate and economic losses globally. The conventional cancer therapies available in the market cause severe side effects and relapse of cancer. These factors have led to increase in funding for the R&D development of various novel therapies. As cancer gene therapy causes fewer side effects and does not harm the surrounding cells, the therapy is gaining popularity from many academic research laboratories, small biotech firms, and large pharmaceutical companies.

The rise in prevalence of cancer and increase in biotechnological funding that will encourage the R&D activities for cancer gene therapy are the major factors driving the market growth. In addition, benefits of cancer gene therapy over conventional cancer therapies and increase in government support fuel the growth of the cancer gene therapy market. Furthermore, ethical acceptance of gene therapy for cancer treatment, short duration treatment, and the advancement in this field boost the market growth. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market.

Gene transfer therapy is expected to be a lucrative segment for the market players as it is the fastest growing segment. The therapy involves the introduction of new genes into the tumor cells. It is an emerging cancer treatment method and seem to show positive results in the preclinical and clinical studies.

The employment of cancer gene therapy is highest in North America, owing to the increase in funding for the R&D activities, high prevalence rate of cancer, and increase in disposable income among customers. Although the use of cancer gene therapy in Asia-Pacific and LAMEA region is low, the adoption rate is expected to increase due to rise in disposable income, rise in incidence rate of cancer, and government initiative to improve healthcare infrastructure, which in turn fuel the market growth.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Cancer Gene Therapy Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3690
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4099
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $4999
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6004
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8373
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts